Phio Pharmaceuticals Corp. (PHIO) financial statements (2021 and earlier)

Company profile

Business Address 257 SIMARANO DRIVE
MARLBOROUGH, MA 01752
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments71541311814
Cash and cash equivalents7154135811
Short-term investments    6 3
Restricted cash and investments  0    
Prepaid expense   00  
Other undisclosed current assets0000000
Total current assets:71541311915
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment0000000
Long-term investments and receivables   0   
Accounts and financing receivable, after allowance for credit loss   0   
Deposits noncurrent assets      0
Other noncurrent assets0 0000 
Total noncurrent assets:1000000
TOTAL ASSETS:81541311915
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2223223
Accounts payable1111100
Accrued liabilities1122112
Employee-related liabilities     11
Debt0      
Deferred revenue and credits   00
Other undisclosed current liabilities     (1)(1)
Total current liabilities:2223212
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0
Total noncurrent liabilities:0      
Total liabilities:2223212
Stockholders' equity
Stockholders' equity attributable to parent, including:614211935
Common stock00 0000
Additional paid in capital101998073664841
Accumulated deficit(95)(86)(79)(66)(57)(47) 
Other undisclosed stockholders' equity attributable to parent   4 2(36)
Other undisclosed stockholders' equity      8
Total stockholders' equity:6142119313
Other undisclosed liabilities and equity     5 
TOTAL LIABILITIES AND EQUITY:81541311915

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net  000
Gross profit:0000000
Operating expenses(9)(8)(14)(9)(10)(9)(21)
Operating loss:(9)(7)(14)(9)(10)(9)(21)
Nonoperating income (expense)00(0)000 
Other nonoperating income (expense)  (0)0(0)0 
Loss from continuing operations before equity method investments, income taxes:(9)(7)(14)(9)(10)(9)(21)
Other undisclosed income from continuing operations before income taxes     00
Loss from continuing operations before income taxes:(9)(7)(14)(9)(10)(9)(21)
Income tax benefit322443 
Net loss:(6)(5)(12)(5)(6)(5)(21)
Other undisclosed net loss attributable to parent(3)(2) (4)(4)(3) 
Net loss attributable to parent:(9)(7)(12)(9)(10)(9)(21)
Preferred stock dividends and other adjustments   (2)(0)(4)(9)
Net loss available to common stockholders, diluted:(9)(7)(12)(11)(10)(13)(30)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(6)(5)(12)(5)(6)(5)(21)
Comprehensive loss, net of tax, attributable to parent:(6)(5)(12)(5)(6)(5)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: